Value proposition

We have merged with Bristol Myers Squibb creating a leading biopharma company, ideally positioned to discover, develop and deliver innovative medicines for patients fighting serious diseases. Visit www.bms.com to continue to learn more about our work to produce the next generation of medicines to treat cancer and other serious diseases.

For more information on the acquisition, see our press release at: http://bit.ly/3UbQcnl

Hematology, Oncology, Inflammation, Immunology, Cancer, R&D, Innovation, Immunooncology, biopharma, Epigenetics, Protein Homeostasis, Translation Medicine, and Orphan diseases